Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 35.8%

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 250,300 shares, an increase of 35.8% from the February 13th total of 184,300 shares. Currently, 11.2% of the company’s stock are short sold. Based on an average daily volume of 850,600 shares, the short-interest ratio is presently 0.3 days.

GT Biopharma Stock Performance

Shares of GTBP traded up $0.08 during trading hours on Friday, hitting $2.56. 20,465 shares of the company were exchanged, compared to its average volume of 583,197. The firm’s 50 day moving average is $2.33 and its 200-day moving average is $2.49. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66. The company has a market cap of $6.49 million, a PE ratio of -0.37 and a beta of 0.59.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GTBP shares. Roth Mkm initiated coverage on GT Biopharma in a research note on Monday, December 2nd. They issued a “buy” rating and a $11.00 price target for the company. Roth Capital upgraded shares of GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.